Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $34.95 Average Price Target from Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been given an average recommendation of “Moderate Buy” by the twenty-one ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $34.95.

NTLA has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Intellia Therapeutics to a “sell” rating in a report on Monday, March 3rd. Wolfe Research raised shares of Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 price target for the company in a research note on Monday, April 21st. Guggenheim lowered their target price on shares of Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, May 12th. Chardan Capital reissued a “buy” rating and issued a $68.00 price objective on shares of Intellia Therapeutics in a research note on Friday, May 9th. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a research note on Friday, February 28th.

Intellia Therapeutics Trading Up 6.7%

Shares of NASDAQ:NTLA opened at $8.09 on Wednesday. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.18. The company has a 50-day moving average price of $7.93 and a 200 day moving average price of $10.06. The company has a market cap of $837.99 million, a price-to-earnings ratio of -1.49 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. The firm’s revenue for the quarter was down 42.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.12) EPS. As a group, equities analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current year.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NTLA. Ensign Peak Advisors Inc raised its stake in Intellia Therapeutics by 2.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock worth $457,000 after buying an additional 1,100 shares during the period. HighTower Advisors LLC boosted its position in shares of Intellia Therapeutics by 8.2% during the 1st quarter. HighTower Advisors LLC now owns 16,921 shares of the company’s stock valued at $120,000 after acquiring an additional 1,282 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Intellia Therapeutics by 14.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock valued at $157,000 after buying an additional 1,582 shares in the last quarter. Arizona State Retirement System lifted its position in Intellia Therapeutics by 6.1% in the fourth quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock valued at $327,000 after purchasing an additional 1,615 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in shares of Intellia Therapeutics by 10.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company’s stock valued at $210,000 after buying an additional 1,634 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.